<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11139307</article-id><article-id pub-id-type="pmc">2363622</article-id><article-id pub-id-type="pii">6691539</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1539</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>P W M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Muers</surname><given-names>M F</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Peake</surname><given-names>M D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Poulter</surname><given-names>K M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gurney</surname><given-names>E M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Napp</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hepburn</surname><given-names>P M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>J M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>ICRF Cancer Medicine Research Unit, St James's University Hospital, Beckett Street, Leeds, UK</aff><aff id="aff2"><label>2</label>Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK</aff><aff id="aff3"><label>3</label>Pontefract General Infirmary, Friarwood Lane, Pontefract, WF8 1PL, UK</aff><aff id="aff4"><label>4</label>Northern and Yorkshire Clinical Trials and Research Unit, 17 Springfield Mount, Leeds, LS2 9NG, UK</aff><pub-date pub-type="epub"><day>01</day><month>01</month><year>2001</year></pub-date><pub-date pub-type="ppub"><month>01</month><year>2001</year></pub-date><volume>84</volume><issue>1</issue><fpage>19</fpage><lpage>24</lpage><history><date date-type="received"><day>19</day><month>04</month><year>2000</year></date><date date-type="rev-recd"><day>26</day><month>08</month><year>2000</year></date><date date-type="accepted"><day>13</day><month>09</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A randomized trial was conducted to determine whether administration of Amifostine with chemotherapy for small cell lung cancer could decrease the toxicity. 84 patients with small cell lung cancer of favourable prognosis (limited disease, performance status 0&#x02013;1; limited disease with performance status 2 but normal sodium and alkaline phosphatase, or extensive diseas with performance status 0&#x02013;1, normal sodium and alkaline phosphatase) received treatment with Ifosfamide 3 g/m<sup>2</sup>intravenously, Carboplatin (Glomerular filtration rate + 25) &#x000d7;6 mg intravenously, Etoposide 50 mg orally, twice daily, for 7 days, every 3 weeks. Patients were randomized to receive amifostine 740 mg/m<sup>2</sup>immediately prior to the intravenous drugs (<italic>n</italic> = 42) or to receive chemotherapy alone (<italic>n</italic> = 42). The two groups were similar with respect to baseline prognostic factors. There was no significant difference in the occurrence of grade III or IV neutropenia or thrombocytopenia between the two groups, nor in the response rate or overall survival, for which the median was 11 months in the chemotherapy only group and 14 months in the group treated with amifostine. This study has not shown a protective effect from the use of amifostine with this regimen and there does not appear to be any effect upon the efficacy of treatment. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>small cell lung cancer</kwd><kwd>chemotherapy</kwd><kwd>myelotoxicity</kwd><kwd>chemoprotection</kwd><kwd>amifostine</kwd><kwd>survival</kwd></kwd-group></article-meta></front></article>


